ImmunityBio (IBRX) shares rise 2% on global expansion hopes

IBRX ImmunityBio Inc

$10.40 +1.12%

View chart & analysis →

OTLK +1.79% CAPR -13.07% HIMS +2.31%

1. 1IBRX climbed more than 2% on Sunday night as retail investors looked ahead to BTIG's virtual biotech conference on Tuesday and Wednesday, hoping for news on global partnerships and expansion.
2. 2The FDA has accepted ImmunityBio's application to expand the indication of its bladder cancer therapy Anktiva in combination with BCG, with a decision date set for January 6, 2027.
3. 3Founder Soon-Shiong mentioned the NK-cell platform and global expansion, but with no related announcement in July, investors are split between disappointment and hope.

Source Stocktwits +2 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →